Figure 4
Figure 4. T-Rapa cell infusion results in predominate donor CD4+ T-cell reconstitution. (A) Percent donor T lymphoid chimerism for each patient at days 14, 28, and 100 after allogeneic hematopoietic stem cell transplant (SCT) (top; ***, day 28 > day 14 and day 100 > day 28; P < .0001). Post-SCT numbers of donor vs host CD4+ or CD8+ T cells were estimated by multiplying CD4 and CD8 cell absolute numbers by percent CD3 chimerism values. The figure shows median estimated values for absolute numbers of donor and host CD4+ T cells (left) and CD8+ T cells (right) at days 14, 28, and 100 post-SCT (comparisons are day 28 vs day 14 and day 100 vs day 28; ***P < .001; **P < .01; *P < .05; between n = 23 and n = 33 evaluated for each paired analysis). (B) Percent donor myeloid chimerism for each patient at days 14, 28, and 100 post-SCT (***, day 28 > day 14 and day 100 > day 28; P < .0001). NS, not significant.

T-Rapa cell infusion results in predominate donor CD4+ T-cell reconstitution. (A) Percent donor T lymphoid chimerism for each patient at days 14, 28, and 100 after allogeneic hematopoietic stem cell transplant (SCT) (top; ***, day 28 > day 14 and day 100 > day 28; P < .0001). Post-SCT numbers of donor vs host CD4+ or CD8+ T cells were estimated by multiplying CD4 and CD8 cell absolute numbers by percent CD3 chimerism values. The figure shows median estimated values for absolute numbers of donor and host CD4+ T cells (left) and CD8+ T cells (right) at days 14, 28, and 100 post-SCT (comparisons are day 28 vs day 14 and day 100 vs day 28; ***P < .001; **P < .01; *P < .05; between n = 23 and n = 33 evaluated for each paired analysis). (B) Percent donor myeloid chimerism for each patient at days 14, 28, and 100 post-SCT (***, day 28 > day 14 and day 100 > day 28; P < .0001). NS, not significant.

Close Modal

or Create an Account

Close Modal
Close Modal